Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 11338026

    Identification of immunologically protective neo-epitopes for the treatment of cancers

    UNIVERSITY OF CONNECTICUT · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11337998

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11339213

    Methods and compositions for treatment of cancer

    MEREO BIOPHARMA 5, INC. · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11338003

    Methods of treating bladder cancer with an oncolytic virus

    CG ONCOLOGY, INC. · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11324822

    Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

    Syndax Pharmaceuticals, Inc. · Granted Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11311578

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11311517

    Combination of small molecule CD-47 inhibitors with other anti-cancer agents

    Aurigene Discovery Technologies Limited · Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11311485

    Self-assembled particles for targeted delivery of immunomodulators to treat autoimmunity and cancer

    Northwestern University · Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11312787

    Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis

    The Regents of the University of California · Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11304980

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11304988

    Inhibiting tumor cell migration by inhibition of kinesin light chain 1, variant 1 (KLC1C)

    Northwestern University · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11304950

    Methods for treating testicular and ovarian adrenal rest tumors

    SPRUCE BIOSCIENCES, INC. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11304979

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. WO 2022074143

    DÉRIVÉS DE BENZO[H]QUINAZOLIN-4-AMINE ET DE THIÉNO[3,2-H]QUINAZOLIN-4-AMINE POUR LE TRAITEMENT DU CANCER

    BASILEA PHARM INT AG [CH] · Granted Thu Apr 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11298378

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11293009

    Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

    Iovance Biotherapeutics, Inc. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11291687

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11292842

    Anti-PD-1 antibodies for treatment of lung cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11291663

    Methods of treating cancer with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11285154

    Methods and compositions for treating cancer

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11285194

    Combination immunotherapy approach for treatment of cancer

    Calidi Biotherapeutics, Inc. · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11279934

    Methods for treating cancer using nucleic acids targeting MDM2 or MYCN

    Phio Pharmaceuticals Corp. · Granted Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11279768

    Anti-cancer antibodies, combination therapies, and uses thereof

    PRECISION BIOLOGICS, INC. · Granted Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11273181

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11273180

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 2022072166

    METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS

    ADVANCED ACCELERATOR APPLICATIONS S A [FR] · Granted Thu Mar 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11266746

    Therapeutic antitumor combination of a TLR4 ligand with other treatments

    The United Slates of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11266694

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11266726

    Compositions and methods for the treatment of HER2-expressing solid tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. WO 2022043557

    MÉTHODE DE TRAITEMENT DE CANCERS EXPRIMANT LE PSMA

    ADVANCED ACCELERATOR APPLICATIONS INT SA [CH] · Granted Thu Mar 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. WO 2022043558

    MÉTHODE DE TRAITEMENT DE CANCERS EXPRIMANT LE PSMA

    ADVANCED ACCELERATOR APPLICATIONS INT SA [CH] · Granted Thu Mar 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11261237

    Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11260058

    Compositions and method of treating cancer

    The Regents of the University of California · Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11254912

    Methods and compositions for treating cancer

    CRISPR THERAPEUTICS AG · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11253522

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    The Regents of the University of California · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11254913

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11254752

    Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11246859

    Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers

    Biomed Valley Discoveries, Inc. · Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11246881

    Nanoparticle to target cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11246950

    Combination cancer immunotherapy with pentaaza macrocyclic ring complex

    Galera Labs, LLC · Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11246858

    Immunoresponsive methods of treating tumors

    INSTITUT PASTEUR DE MONTEVIDEO · Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11241456

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11235044

    Cancer vaccines targeting MUC16 and uses thereof

    Inovio Pharmaceuticals, Inc. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11234971

    Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent

    Corcept Therapeutics Incorporated · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11229700

    Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition

    Ludwig-Maximilians-Universitat Munchen · Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11230596

    Methods for treatment of cancer comprising TIGIT-binding agents

    MEREO BIOPHARMA 5, INC. · Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11219614

    Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound

    Galera Labs, LLC · Granted Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11220670

    Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

    Iovance Biotherapeutics, Inc. · Granted Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.